פרק 9: האם התרופות הממריצות יעילות בטווח הארוך?

רשימת מקורות

1. CHADD. Medication Management. Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). Last retrieved on November 16, 2021, from: https://chadd.org/for-adults/medication-management/; Retrieved on November, 2021.
2. APA. Diagnostic and Statistical Manual of  Mental Disorders, 5th edition, Text Revision (DSM-5-TR). American Psychiatric Association.  Washington, DC; 2022.
3. Barkley RA. This is how you treat ADHD based off science, Dr Russell Barkley part of 2012 Burnett Lecture. keynote lecture at the 2012 Burnett Seminar for Academic Achievement, last retrieved on November 16, 2021, from:  https://www.youtube.com/watch?v=_tpB-B8BXk0; 2012.
4. Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European psychiatry. 2019;56:14-34.
5. נובורטיס ישראל. עלון לצרכן לפי תקנות הרוקחים של תרופת הריטלין. נובורטיס פארמה, בזל, שווייץ. עלון זה נבדק ואושר על-ידי משרד הבריאות בפברואר 2017.; 2017.
6. Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H. Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases. Biological psychiatry. 2019;86(5):335-343.
7. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of general psychiatry. 1999;56(12):1073-1086.
8. Schwarz A. ADHD nation: Children, doctors, big pharma, and the making of an American epidemic. Simon and Schuster; 2017.
9. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754-761.
10. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. Journal of the American Academy of Child & Adolescent Psychiatry. 2007;46(8):989-1002.
11. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with ADHD (MTA) Part I: Executive Summary. Journal of Attention Disorders. 2008;12(1):4-14.
12. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child & Adolescent Psychiatry. 2007;46(8):1015-1027.
13. Miranda C. ADHD drugs could stunt growth. Daily Telegraph. Last retrieved on June 19, 2024 from: https://www.dailytelegraph.com.au/adhd-drugs-could-stunt-growth/news-story/2b8dce2e2cb333cc2277218b6404f27d; 2007.
14. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child & Adolescent Psychiatry. 2009;48(5):484-500.
15. Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. Journal of Child Psychology and Psychiatry. 2017/06/01 2017;58(6):663-678. doi:10.1111/jcpp.12684
16. Boland H, DiSalvo M, Fried R, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of Psychiatric Research. 2020/04/01/ 2020;123:21-30. doi:https://doi.org/10.1016/j.jpsychires.2020.01.006
17. Currie J, Stabile M, Jones L. Do stimulant medications improve educational and behavioral outcomes for children with ADHD? Journal of health economics. 2014;37:58-69.
18. Whitely M. The rise and fall of ADHD child prescribing in Western Australia: Lessons and implications. Australian & New Zealand Journal of Psychiatry. 2012/05/01 2012;46(5):400-403. doi:10.1177/0004867412444864
19. Zur M, Magnezi R, Portuguese S, Reuveni I, Kedem R, Fruchter E. The Impact of Adherence to Treatment for ADHD on the Quality of Military Service – The Israeli Military Experience. Military Medicine. 2018;183(9-10):e518-e524. doi:10.1093/milmed/usy161
20. Chen VC-H, Yang Y-H, Liao Y-T, et al. The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan. PloS one. 2017;12(3)
21. Mohr-Jensen C, Müller Bisgaard C, Boldsen SK, Steinhausen H-C. Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence and the Risk of Crime in Young Adulthood in a Danish Nationwide Study. Journal of the American Academy of Child & Adolescent Psychiatry. 2019/04/01/ 2019;58(4):443-452. doi:https://doi.org/10.1016/j.jaac.2018.11.016
22. Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. Journal of Child Psychology and Psychiatry. 2014;55(8):878-885.
23. Liang SH-Y, Yang Y-H, Kuo T-Y, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Research in developmental disabilities. 2018;72:96-105.
24. Merzon E, Manor I, Rotem A, et al. ADHD as a Risk Factor for Infection With Covid-19. Journal of Attention Disorders. 2021/11/01 2020;25(13):1783-1790. doi:10.1177/1087054720943271
25. Pollak Y, Poni B, Gershy N, Aran A. The role of parental monitoring in mediating the link between adolescent ADHD symptoms and risk-taking behavior. Journal of attention disorders. 2020;24(8):1141-1147.
26. Blasco-Fontecilla H. Medicalization, wish-fulfilling medicine, and disease mongering: toward a brave new world? Revista clinica espanola. 2014;214(2):104-107.
27. Wolinsky H. Disease mongering and drug marketing. EMBO reports. 2005/07/01 2005;6(7):612-614. doi:10.1038/sj.embor.7400476
28. Lu Y, Sjölander A, Cederlöf M, et al. Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry. 2017;74(8):815-822. doi:10.1001/jamapsychiatry.2017.1472
29. Ophir Y, Shir-Raz Y. Manipulations and Spins in Attention Disorders Research: The Case of ADHD and COVID-19. Ethical Hum Psychol Psychiatry. 2020;22:98-113. doi:10.1891/EHPP-D-20-00024
30. Vaa T. ADHD and relative risk of accidents in road traffic: A meta-analysis. Accident Analysis & Prevention. 2014;62:415-425.
31. Ophir Y, Shir-Raz Y. Discrepancies in Studies on ADHD and COVID-19 Raise Concerns Regarding the Risks of Stimulant Treatments During an Active Pandemic. Ethical Human Psychology and Psychiatry. 2022;25(1)doi:10.1891/EHPP-2022-0011
32. Ophir Y. Evidence that the Diagnosis of ADHD Does Not Reflect a Chronic Bio-Medical Disease. Ethical Human Psychology and Psychiatry. 2022;23-2
33. CHADD. Managing Medication. CHADD:  Children and Adults with ADHD , 4221 Forbes Blvd, Suite 270, Lanham, MD, 20706. Last retrieved on November 16, 2021 from: https://chadd.org/for-parents/managing-medication/; Retreived on November 2021.

בחזרה לעמוד הראשי של רשימת המקורות של הספר, לחצו כאן.